Nucleics
Sydney, Australia· Est.
Australian Sanger sequencing tools that boost read quality and length for genomics labs.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Australian Sanger sequencing tools that boost read quality and length for genomics labs.
Technology Platform
Proprietary Sanger sequencing software and reagents that improve basecalling accuracy and extend high‑quality read length using calibration standards and advanced signal processing.
Opportunities
Increasing demand for high‑accuracy Sanger validation in clinical diagnostics and NGS quality control offers growth for Nucleics' software and reagent suite.
Risk Factors
Competition from alternative basecalling tools and the shift toward long‑read NGS platforms could reduce market size for Sanger‑based solutions.
Competitive Landscape
Key competitors include Phred, LifeTrace, and other basecalling software; Nucleics differentiates through integrated hardware/software solutions and proprietary calibration reagents.